Health and Fitness Health and Fitness
Tue, December 6, 2011
Mon, December 5, 2011
Sun, December 4, 2011
Fri, December 2, 2011
Thu, December 1, 2011
Wed, November 30, 2011
[ Wed, Nov 30th 2011 ] - Market Wire
Watson Launches Generic LIPITOR
Tue, November 29, 2011
Mon, November 28, 2011
Sun, November 27, 2011
Fri, November 25, 2011
Thu, November 24, 2011
Wed, November 23, 2011
[ Wed, Nov 23rd 2011 ] - Market Wire
00 a.m. EST
Tue, November 22, 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
BD Board Increases Dividend
Mon, November 21, 2011

NPS Pharmaceuticals to Present at Deutsche Bank BioFEST Conference


//health-fitness.news-articles.net/content/2011/ .. present-at-deutsche-bank-biofest-conference.html
Published in Health and Fitness on Tuesday, November 29th 2011 at 13:20 GMT by Market Wire   Print publication without navigation


BEDMINSTER, N.J.--([ ])--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the 2011 Deutsche Bank BioFEST Conference in Boston on Tuesday, December 6, 2011 at 9:45 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investorsa calendar of events page on the NPS website at [ http://www.npsp.com/events ].

About NPS Pharmaceuticals

NPS Pharmaceuticals is an outsourcing-based development company focused on bringing biopharmaceuticals to patients with rare disorders and few, if any, therapeutic options. The company is advancing two Phase 3 registration programs, GATTEX (teduglutide) in adult short bowel syndrome (SBS) and NATPARATM (parathyroid hormone 1-84 [rDNA origin] injection) in hypoparathyroidism. NPSa earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical.


Publication Contributing Sources